Lorazepam Injection Recalled for Out-of-Specification Impurities and Degradation
Hikma Pharmaceuticals is recalling Lorazepam Injection vials due to out-of-specification impurities and degradation products found during quality testing of retained samples.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of an injectable pharmaceutical due to out-of-specification impurities and degradation products. Quality failures in injectable medications represent a risk-of-harm situation where drug safety and efficacy could be compromised, even though no illnesses or injuries have been reported to date.
Plain-English summary
Hikma Pharmaceuticals USA Inc. is recalling Lorazepam Injection, USP, 2mg/mL, in 1 mL vials, due to out-of-specification results observed for total related compounds during testing of retained samples.
The recalled product includes lot number 070088 with expiration date July 2023, distributed nationwide in the United States. Approximately 713,550 vials are affected. The product is marketed under the brand name Lorazepam by Novaplus and is manufactured by Hikma in Berkeley Heights, New Jersey.
Lorazepam is a benzodiazepine medication administered by injection. Quality and purity are critical for injectable medications. Out-of-specification impurities or degradation products may affect drug safety and efficacy. Healthcare providers and patients with the affected product should consult their healthcare professional regarding this recall.
The recalled product
- Product
- LORAZEPAM (LORAZEPAM)
- Brand
- LORAZEPAM
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Category
- Drug
- Affected units
- 713,550
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 070088
- exp. date 07/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Hikma Pharmaceuticals USA Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · LORAZEPAM
- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- HighLorazepam Tablets Recalled Due to Sub-Potency and Failed Stability Testing
FDA (Drugs) · 2025-02-26
- HighLorazepam Tablets Recalled for Failed Impurity and Potency Specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam injection vials recalled for elevated impurities and degradation
FDA (Drugs) · 2023-05-24
Same manufacturer · Hikma Pharmaceuticals USA Inc.
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateAlendronate Sodium Oral Solution Recalled for Out-of-Specification Assay Results
FDA (Drugs) · 2026-05-06
- SevereFDA Recalls Acetaminophen Injection Due to Labeling Mix-up
FDA (Drugs) · 2024-08-28
- HighMorphine Sulfate Ampuls Recalled for Expired Filters in Cartons
FDA (Drugs) · 2024-03-27
- HighGanciclovir injection vials contain mislabeled cladribine vials in cartons
FDA (Drugs) · 2023-01-04
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08